Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC

VernacularTitle: 核苷（酸）类似物抗病毒治疗预防乙型肝炎病毒相关肝细胞癌：治疗时机及药物选择
Author: Chao HAN ¹ ; Pingping LAI ; Xiaoguang DOU
Author Information

1. Department of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang 110022, China
Publication Type:Journal Article
Keywords: Carcinoma, hepatocellular; Hepatitis B virus; Nucleos(t)ide analogues
From: Chinese Journal of Hepatology 2019;27(11):827-830
CountryChina
Language:Chinese
Abstract: Hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC) in China. The occurrence of HCC can significantly be reduced with effective long-term antiviral treatment. Since the widespread clinical use of nucleos(t)ide analogues, such as entecavir and tenofovir that has a strong potency and high genetic barrier to resistance; the detection rate of HBV DNA in serum of patients with chronic hepatitis B is no more than 85% ~ 95%, but HCC can still occur in a small number of patients. This article will review whether the timing and selection of NAs treatment differ to prevent and reduce the incidence of HCC.